Galina Zhulai

Galina Zhulai

Laboratory of genetic, Institute of Biology of Karelian Research Centre, Petrozavodsk, Kareliya, Russia
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
GZGalina Zhulai
Galina Zhulai
EOEugenia Oleinik
Eugenia Oleinik
MSMikhail Shibaev
Mikhail Shibaev
KIKirill Ignatev
Kirill Ignatev
The immunosuppressive effect of adenosine in the microenvironment of a tumor is well established. Presently, researchers are developing approaches in immune therapy that target inhibition of adenosine or its signaling such as CD39 or CD73 inhibiting antibodies or adenosine A2A receptor antagonists. However, numerous enzymatic pathways that control ATP-adenosine balance, as well as understudied intracellular adenosine regulation, can prevent successful immunotherapy. This review contains the latest data on two adenosine-lowering enzymes: adenosine kinase (ADK) and adenosine deaminase (ADA). ADK deletes adenosine by its phosphorylation into 5′-adenosine monophosphate. Recent studies have revealed an association between a long nuclear ADK isoform and an increase in global DNA methylation, which explains epigenetic receptor-independent role of adenosine. ADA regulates the level of adenosine by converting it to inosine. The changes in the activity of ADA are detected in patients with various cancer types. The article focuses on the biological significance of these enzymes and their roles in the development of cancer. Perspectives of future studies on these enzymes in therapy for cancer are discussed.

22 December 2021 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
GZGalina Zhulai
Galina Zhulai
EOEugenia Oleinik
Eugenia Oleinik
The programmed death (PD)‐1/PD‐ligand (PD‐L) pathway and regulatory T cells (Tregs) are essential for the maintenance of immune tolerance. Their activation in the tumour microenvironment contributes to the evasion of the transformed cells from the immune surveillance and the suppression of an antitumour immune response. Therefore, PD‐1/PD‐L1 and Tregs are important targets for cancer immunotherapy. Our review focuses on the current role of the PD‐1/PD‐L1 axis in Treg development and function in the tumour microenvironment. We also discuss combination therapy with PD‐1/PD‐L1 inhibitors and Treg‐modulating agents affecting the adenosinergic pathway, TGF‐β signalling, immune checkpoints and other approaches to downregulation of Tregs.

1 April 2021 in Human Immunology
Verified
Journal Article
Closed access
ACAlexey Churov
Alexey Churov
GZGalina Zhulai
Galina Zhulai

16 April 2020 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
EOE. K. Oleinik
E. K. Oleinik
MSM. I. Shibaev
M. I. Shibaev
KIK. S. Ignatiev
K. S. Ignatiev
VOV. M. Oleinik
V. M. Oleinik
GZGalina Zhulai
Galina Zhulai
Микроокружение опухоли: формирование иммунного профиля

1 January 2018 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
GZGalina Zhulai
Galina Zhulai
ACAlexey Churov
Alexey Churov
EOE. K. Oleinik
E. K. Oleinik
ARA. A. Romanov
A. A. Romanov
PCPetrozavodsk Republic Oncology Center
Petrozavodsk Republic Oncology Center
VOV. M. Oleinik
V. M. Oleinik

5 April 2016 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
PKP. N. Kravchenko
P. N. Kravchenko
GZGalina Zhulai
Galina Zhulai
AЧArray Викторович Чуров
Array Викторович Чуров
EOE. K. Oleinik
E. K. Oleinik
VOV. M. Oleinik
V. M. Oleinik
AБArray Юрьевна Барышева
Array Юрьевна Барышева
Background: Rheumatoid arthritis (RA) is an inflammatory rheumatic disease, associated with a dysfunction of the T cell-mediated tolerance and leading to the disability of working population. The regulatory CD4+ T cells are play important role in the regulation of autoimmunity and can suppress immune responses. With that, there is no consensus on the content of these lymphocytes and their role in the pathogenesis of RA. Objective: The aim of the study was to assess the content of peripheral blood regulatory T cells (Treg) according to the expression of membrane markers CD4, CD25, CD127 and intracellular FOXP3 marker, as well as the expression of two functional molecules (CTLA-4 and CCR4) in Treg cells of patients with RA. Methods: Peripheral blood samples of RA patients (mean age 61,1±10,5) and healthy controls (mean age 52,2±14,0) were analyzed. Cell count and the expression level of molecules were assessed by flow cytometry. Results: Peripheral blood samples of 36 RA patients and 20 healthy donors were analyzed. The number of the cells with Treg-associated phenotypes CD4+CD25hi and CD4+CD25hiCD127low/– was higher in RA patients in comparison with healthy donors. Increased levels of RA CD4+ T cells expressing FOXP3 were also observed. This may be due to increasing in the number of CD4+FOXP3+CD25- lymphocytes, whereas the content of RA CD4+FOXP3+CD25+ Treg cells was at the level of the control. The expression of the functional molecule CTLA-4 in Treg cells of patients with RA was not different from the control, while the expression level of the chemokine receptor CCR4, which provides migration of lymphocytes at sites of inflammation and barrier tissues, was significantly increased in RA patients. Conclusion: Increase in the levels of certain Treg-associated lymphocyte populations were detected in peripheral blood of RA patients. During the natural course of RA, alterations in the level of the chemokine receptor CCR4 might indicate the enhanced lymphocyte migration.